Alirocumab

Therapeutic indications

Alirocumab is indicated for:

Primary heterozygous familial hypercholesterolaemia, primary non-familial hypercholesterolaemia, mixed dyslipidaemia

Population group: both men and women, only adults (18 years old or older)

Alirocumab is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

The effect of alirocumab on cardiovascular morbidity and mortality has not yet been determined.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Established atherosclerotic cardiovascular disease

Population group: both men and women, only adults (18 years old or older)

Alirocumab is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

  • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: PRALUENT Solution for injection
< Previous: Overview
Next: Precautions >